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Abstract 
In the last decade guanidines have attracted attention as valuable hydrogen bond-based catalysts while 
they have long been considered as organic superbases with a broad scope of synthetic applicability. Their 
easy modification has also expanded their capacity to form complexes with a wide range of metal salts as 
effective metal scavengers. All these attractive aspects have promoted a huge growth of this area in the 
field of organic synthesis and examples of such reactions have been collected in numerous reviews and 
some books. Moreover, this structural motif is also present in a large number of natural products and 
biologically active compounds, which exhibit appealing properties and play important roles in medicinal 
chemistry. In this highlight, we will only cover the synthesis and properties of biologically active 
guanidine containing peptides reported in the last three years. 
 
 
 
1 Introduction 
The guanidine motif is present in a great number of natural compounds that carry out different and 
important functions in animals and plants (Fig. 1).[1] Due to their appealing properties, many research 
groups are working on the synthesis of these natural products and their derivatives, as well as exploring 
new properties and novel potential uses that they might exhibit.[2] Among these interesting uses, 
guanidines have been mainly explored as efficient “superbases” for organic synthesis,[3] useful 
organocatalysts,[4] exchange membrane transporters,[5] and peptides or peptide mimetics,[6] which is the 
main topic of this highlight. Additionally, many guanidinium compounds have been employed as viable 
targets for drug discovery due to their potent biological activities.[1] 
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Fig. 1 Active guanidine skeletons in natural compounds: 1,[7] 2,[8] 3,[6d] 4,[9] 5[10] and 6.[11] 
 
This highlight will focus on a specific part of this huge and interesting field: peptides containing the 
guanidine motif, covering the most significant reported work since 2010.[12] 
 
2 Synthesis 
There is a great number of peptides containing guanidine moieties within their structures. Due to this fact, 
there are several common synthetic strategies for introducing the guanidine group into peptides. The most 
common approach is adding an electrophilic amidine species to a peptide possessing an amine group that 
can act as a nucleophile.[13] In spite of the possible drawbacks related to the synthesis of peptides, such as 
their high insolubility, the presence of different active functional groups, the need for protecting groups, 
as well as the position and steric hindrance of the nucleophilic amine, some selected peptides have been 
obtained following the methods disclosed below: 
 
a. Protected thiourea[14] or S-alkyl-iso-thiourea[15] derivatives are guanylating agents in this type 
of transformation (Fig. 2). Normally, these reactions are carried out with HgCl2 as the catalyst 
and an organic base, providing good results with moderate to excellent yields. These 
guanylating agents are synthesized in high yield from easily available precursors, since 
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thioureas are very versatile starting materials. However, a strong electron-withdrawing group is 
required to activate the thiourea and the N,N’-bis-Boc-protection, which is easy to remove, 
seems to be the most general approach. Bis-protected thioureas are found to be effective with 
unreactive amines, such as aromatic amines. This approach is also useful for the synthesis of 
terminal guanidines; however, there are often more difficulties with the synthesis of internal 
amines. S-alkyl-iso-thioureas have been used successfully for the preparation of disubstituted 
guanidines under Mitsunobu conditions with moderate to excellent reactivities. 
 
Fig. 2 Substituted biologically active guanidine peptides: 7,[16] 8,[17] 9,[18] and 10.[19] 
 
b. Other common reagents used for guanylating peptide derivatives, without using HgCl2, are 1H-
pyrazole-1-carboxamidines (Fig. 3).[20] This is an appealing and straightforward approach due 
to its operational simplicity and the mild reaction conditions employed in these syntheses when 
compared with other procedures. These processes only require stoichiometric amounts of the 
guanylating agent and an equimolar amount of an organic base, leading to attractive peptide 
structures in good to excellent yields. Moreover, these reagents exhibit enough reactivity for 
solid-phase peptide synthesis where other guanylating agents fail to do so. Although they have 
been found less active against sterically hindered secondary amines and more extreme 
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conditions are required to guanylate anilines, they can still be used efficiently in the presence of 
a variety of functional groups. 
 
 
Fig. 3 Synthesis of guanidine containing peptides using 1H-pyrazole-1-carboxamidine: 11,[21] 
12,[22] and 13a-13b.[23] 
 
c. Another interesting method is using N,N’-di-Boc-N’’-triflylguanidine as the guanylating agent 
(Fig. 4).[24] This is a simple method in which the guanylating agent is added to a solution 
containing a slight excess of a nucleophilic amine and one equivalent of a tertiary amine. 
Remarkably, these reactions proceed more quickly in nonpolar solvents (CH2Cl2 and CHCl3), 
although other common procedures use polar solvents, and afford good yields with remarkably 
pure crudes. They could be performed either at room temperature or by heating the solution via 
conventional methods or in a microwave. Primary amines react more quickly than highly 
sterically hindered amines; however, anilines react more slowly but afford excellent yields after 
longer reaction times. In general, N,N’-di-Boc-N’’-triflylguanidine exhibits better reactivity 
when compared with other guanylating agents, making it an interesting option for the synthesis 
of protected guanidines.[24a] 
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Fig. 4 Synthesis of guanidine containing peptides using N,N’-di-Boc-N’’-triflylguanidine: 14[25] 
and 15.[26] 
 
d. There are other useful guanylating agents that can be used as an alternative for the above 
mentioned agents. In those reactions, a nucleophilic amine would be added to carbodiimide 
derivatives,[27] O-methylisourea[28] and benzotriazole derivatives,[29] among other reagents. The 
latter is easily accessible from commercially available S-alkyl-iso-thiourea, and it is the most 
reactive guanylating agent due to the leaving group character of the benzotriazole moiety. It is 
highly efficient for guanylating primary and secondary amines, including anilines and solid 
supports.[30] On the other hand, carbodiimide derivatives are synthesized from the 
corresponding urea or thiourea, which allows the preparation of chiral and different substituted 
carbodiimides, extending the scope and complexity of final guanidine derivatives.  
 
6 
 
Fig. 5 Synthesis of guanidine containing peptides using additional guanylating agents: 16,[31] 
17,[32] and 18.[33] 
 
e. Guanidines have also been involved in Mitsunobu reactions as a crucial step for the synthesis 
of interesting compounds (Fig. 6).[34] In these Mitsunobu reactions, contrary to the methods 
listed before, the guanidine group acts as a nucleophile, exchanging an alcohol group for a 
guanidine group.  
 
Fig. 6 Synthesis of guanidine containing peptides using a Mitsubonu reaction.[35] 
 
It is remarkable that besides normal approaches carried out in solution, many examples of the 
abovementioned syntheses were performed using solid-phase processes.[36] In general, these methods have 
been used extensively and have been proven useful for the synthesis of non-peptide analogues.[2] 
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3 Molecular Recognition 
Guanidine based sensors have attracted the attention of many research groups due to their usefulness in 
molecular recognition. This intriguing property has its roots in the guanidine moiety’s ability to form 
multidentate bonds with its NH groups, resulting in a strong interaction that leads to the recognition of 
many functional groups. In this context, few examples of the use of peptidic compounds bearing 
guanidine groups as sensors for different types of compounds have been reported in the last few years. 
Schmuck’s group reported the use of a guanidininium-containing artificial peptide 20 as a nucleotide 
sensor (Fig. 7). Successful results for the recognition of phosphates and nucleotides derived of adenosine, 
guanosine, cytidine and uridine are reported. It is remarkable that the experiments are carried out in water 
at neutral pH, which might be useful for studies in physiological fluids. Additionally, this method can 
distinguish between adenosine monophosphate (AMP), diphosphate (ADP) and triphosphate (ATP), 
opening a wide range of possibilities for further biochemical research on biological mechanisms 
involving these species.[37] 
 
Fig. 7 Active guanidinium receptor. 
 
Moreover, Zondlo and coworkers modified arginine residues and added them to peptide chains 18 (Fig. 
5). This work showed the specificity and affinity of the synthesized peptides for different SRC Homology 
3 (SH3) domains. This specificity depended on the position of the modified arginine group, its 
stereochemistry, and the length and substituents of its side-chain. Altering the side-chain of the arginine 
amino acids allowed for the important development of specific binding of different arginine derivatives to 
either the Src or the Grb SH3 domains.[33] 
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4 Biological Properties 
It is known that the properties of these peptides are dependent upon the guanidine functional groups of 
their structures.[38] A small modification in the peptide skeleton could lead to the inactivation of the 
peptide or a change in its biological properties. One interesting feature is that this type of compound 
shows good cell penetrating properties, and that makes these peptides suitable for carrying external agents 
across cell-membranes (such as 11 and 13a,b in Fig. 3).[21,23,39] 
Some of these molecules exhibit antibacterial properties, such as ureidomuraymycidine derivative 9 
synthesized by Kurosu and coworkers (Fig. 2).[18] This peptide might be a good precursor for synthesizing 
different muraymycins, which are natural compounds that inhibit the enzyme MraY, an essential enzyme 
for the biosynthesis of the polymer peptidoglycan (PG). This polymer is present in bacterial cell walls and 
it is vital for the survival of these microorganisms, hence the importance of further studies on this kind of 
peptide as antibacterial agents. Cyclic depsipeptide LI-F04a 19[35] also displays promising activity against 
different fungi and Gram-positive bacteria (Fig. 6). 
Other peptides containing guanidines show opioid activity. In all cases, changes in the guanidine groups 
lead to different binding properties with the opioid receptors in vivo[19] and in vitro[40] studies. This is a 
really interesting property because these peptides might be a good alternative for the opiates that are 
currently being used in some treatments with extremely undesirable side effects, such as treatments for 
cocaine addiction.  
Martin, Frankel and coworkers developed a series of arginine derivatives 7 that were shown to be protein 
arginine N-methyltransferases 1 (PRMT1) and PRMT6 inhibitors (Fig. 2).[16] PRMTs are important due to 
their key role methylating arginine groups of DNA and RNA-binding proteins, like small nuclear or 
heterogeneous nuclear ribonucleoproteins (snRNPs or hnRNPs) and histones, which is an important 
process in the modulation of both RNA metabolism and transcription. Therefore, it is not surprising that 
PRMTs play an important part in the modulation and development of certain diseases, such as cancer and 
cardiovascular diseases, as well as in viral replication. Such properties make PRMTs attractive possible 
targets for many substances that interact with their active sites. This approach is really interesting because 
changes in the way that the guanidine groups of certain peptides interact with the active sites of PRMT1 
and PRMT6 are observed. Changes in the guanidine group of the peptide, such as the incorporation of an 
ethyl group with a different number of fluorine atoms, lead to a promising inhibition of these PRMTs.  
Moreover, Steinmetzer and coworkers synthesized diverse peptides 21 containing arginine residues that 
work as furin protease inhibitors (Fig. 8).[41] These inhibitors are involved in important functions in the 
human body, such as the maturation of prohormones, proenzymes and other proproteins in the secretory 
pathway, carrying out a vital function in embryogenesis and homeostasis. Furthermore, furin is believed 
to be implicated in the development of many diseases including cancer, dementia and neurodegenerative 
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disorders. Small changes in the arginine amino acids or in their stereochemistry provide notable 
differences in their inhibition of furin.  
 
Fig. 8 Biologically active guanidine containing peptides. 
 
Furthermore, Burov and coworkers developed amino acid and peptide derivatives attached to creatine by 
peptidic bonds 22 (Fig. 8).[42] Creatine and its analogues have shown neuroprotective activity in 
experimental models of brain stroke, but without a specific creatine transporter (CRT) they cannot cross 
the blood-brain barrier (BBB) efficiently. The compounds reported by these authors show promising 
neuroprotective activity in brain stroke models, both before and after ischemia, which makes them a good 
starting point for the further development of drugs used in stroke treatment. Also, Millo and coworkers 
developed an easy synthesis of different creatine derivatives 12 (Fig. 3), affording a wide range of 
appealing compounds in good yields and under mild reaction conditions.[22] This work might be an 
attractive reference for the synthesis of many creatine analogues and their application in the treatment of 
neurological diseases. 
In addition, Mammi and coworkers studied the biological effect of different peptides with chains of 11 
amino acids (H-Aib-Val-Aib-Glu-Ile-Gln-Leu-Nle-His-Gln-Har-NH2) containing a guanidine group in the 
N-terminal fragment.[43] This research explored the increase of bioactivity and binding of parathyroid 
hormone (PTH) (1-11) analogues. These peptides, which contain 11 amino acids, are synthesized 
emulating the signaling domain of the PTH, corresponding to the N-terminal extracellular domain of the 
hormone composed by residues 1-11. This research is interesting because it complements previous studies 
which pointed to similar compounds as possible anabolic drugs,[44] among other pharmacological 
properties. 
 
5 Conclusion 
We have briefly pointed out the most relevant examples reported in the last three years in the field of 
guanidine containing peptides. The above mentioned easy and versatile methodologies for guanylating a 
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wide range of compounds might be a good starting point for those who aim to synthesize and explore the 
properties of these interesting compounds. Moreover, it will not be a surprise when the number of works 
regarding this topic rises over the next few years due to all the appealing and only partially explored 
properties that different guanidine containing peptide groups show. Although they have already been 
proven useful in many remarkable biological studies, as disclosed above, researchers in the near future 
will be able to discover even more new and fascinating applications for these compounds. 
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